Andreas Peyrl
Medical University of Vienna
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andreas Peyrl as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01356290 · Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsMedical University of Vienna · recruiting · Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:48 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- A taurine and caffeine-containing drink stimulates cognitive performance and well-being.Amino Acids · 2000101 citationsRCR 4.3
- Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.JAMA Oncol · 202345 citationsRCR 4.1
- Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18 F]FDG-PET imaging. Is it of value in asymptomatic patients?Pediatr Blood Cancer · 201838 citationsRCR 2.2
- Pharmacokinetics and toxicity of intrathecal liposomal cytarabine in children and adolescents following age-adapted dosing.Clin Pharmacokinet · 201421 citationsRCR 0.8
- Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma.Pediatr Blood Cancer · 200911 citationsRCR 0.3
- The SimCom-Method: Impact of Simulated Communication Teaching in Pediatric Resuscitation Scenarios.Acad Pediatr · 20250 citationsRCR 0.0